Date Site Confirmed By Sponsor. Non- Confirmation Status. HRA Approval Date. Date Site Confirmed

Transcription

1 Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial First Patient Recruited? Date of First Patient Recruited Invited Selected Approval Date Confirmed By Confirmed Non- Confirmation Status A - Permissions Ready B - Suspended C - Closed D - delayed/ To Start by sponsor by sponsor Delays denied E - Staff availability issues F - No patients seen G - No patients consented H - Contracting delays I - Rare diseases J - Other Reasons for delay correspond to: 17/LO/ /LO/ /SC/ PAPAYA - A phase I study of the anti-pd1 immune checkpoint inhibitor pembrolizumab in combination with radical Chemoradiotherapy in cervix cancer CTC-STOP: Utilising Circulating Tumor Cell (CTC) Counts to Optimise Systemic Therapy of Metastatic Prostate Cancer. plasmamatch - A multiple parallel cohort, nonrandomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctdna screening No 30/03/ /09/ /07/ /09/ /09/2017 Yes 15/02/ /10/ /10/ /10/ /12/ /01/ /01/2017 Y Y Yes 18/01/ /09/ /11/ /09/ /11/ /12/ /12/ /EE/ /LO/ /WM/ PRIMETIME: Post-operative avoidance of Radiotherapy In Minimal risk women: Translational biomarker implementation Hyper: A Phase 1, Dose Escalation Study Of SGI- 110, A Second Generation Hypo-Methylating Agent In Combination With Pembrolizumab (MK3475) In Patients With Refractory Solid PASART 2: Phase II clinical study of concurrent PAzopanib for non metastatic SArcoma patients to be treated with RadioTherapy, localized in the extremities, trunk and chest wall or the head and neck region. Yes 07/06/ /06/ /02/ /11/ /03/ /04/ /06/2017 Y Y Yes 31/01/ /11/ /12/ /10/ /12/ /12/ /12/2016 Yes 16/02/ /12/ /01/ /12/ /12/ /01/ /01/ /LO/ /LO/ /LO ACE: Proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mcrpc) The HeartSpare Plus 1B Trial: A randomised phase II trial comparing the resource impact, acute toxicity, and feasibility of different panlymph node radiotherapy techniques in breast cancer KORTUC-Phase I run in study plus randomised phase II trial testing intra-tumoural hydrogen peroxide as a radiation sensitizer in women with locally advanced/recurrent breast cancer in terms of toxicity and tumour response No 12/06/ /06/ /04/ /06/ /07/ /07/2017 Y Y Yes 12/01/ /10/ /10/ /10/ /10/ /11/ /12/2016 Yes 06/02/ /06/ /12/ /12/ /01/ /01/ /01/ /LO/ A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator s Choice of Chemotherapy in Women with Folate Receptor α positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Yes 25/07/ /02/ /05/ /06/ /07/ /07/ /07/ /LO/ /EM/ /LO/ /LO/ /LO/ /LO/ A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB C) IN COMBINATION WITH AXITINIB (INLYTA ) VERSUS SUNITINIB (SUTENT ) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENALCELL CARCINOMA RomiCar: Phase I/II study to determine the MTD and overall response rate of the combination of romidepsin and carfilzomib in relapsed / refractory peripheral T-cell lymphoma A Global Multicenter Study of Nivolumab in Subjects with Refractory Malignancies with Microsatellite Instability High and Mismatch Repair Deficiency Peri-operative Immuno-Chemotherapy in Operable oesophageal and gastric Cancer (ICONIC Trial) A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone) First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axlspecific antibody-drug conjugate (HuMax -AXL- ADC) in patients with solid tumors Yes 13/04/ /10/ /11/ /11/ /11/ /11/ /03/2017 Y No 17/02/ /01/ /12/ /03/ /05/ /10/2017 Y Y Yes 06/01/ /11/ /11/ /11/ /11/ /12/ /12/2016 No 19/12/ /06/ /06/ /03/ /06/ /07/2017 Y No 21/06/ /01/ /01/ /12/ /01/ /09/2017 Y Yes 29/06/ /11/ /11/ /11/ /11/ /11/ /11/ /LO/ Safety and Pharmacokinetics of ODM-207 in Patients with Selected Advanced Solid Tumours: An Open-Label, Non-Randomised, Uncontrolled, Multicentre, First-in-Human Study with Cohort Expansion Yes 13/02/ /09/ /12/ /12/ /01/ /01/ /01/ /LO/ /LO/ Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration- Resistant Prostate Cancer (mcrpc) (KEYNOTE- 365) A Novel Phase I/IIa Open-label Study of IMM- 101 in Combination with Selected Standard of Care (SOC) Regimens in Patients with Metastatic or Unresectable Cancer at Study Entry Yes 01/02/ /07/ /11/ /11/ /01/ /01/ /01/2017 No 03/11/ /02/ /12/ /04/ /04/ /04/2017 Y Y

2 17/LO/ /LO/ /EM/ A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study A Phase 1b (Open Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating the Efficacy of Gemcitabine and Docetaxel With or Without a Human Anti-PDGFRa Monoclonal Antibody (Olaratumab) in the Treatment of Advanced Soft Tissue Sarcoma A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Yes 03/08/ /08/ /04/ /03/ /06/ /06/ /08/2017 Y Yes 17/08/ /01/ /10/ /11/ /06/ /07/ /08/2017 Y Yes 18/01/ /04/ /12/ /12/ /12/ /12/ /12/ /LO/ /NW/ /EM/ /LO/ /WM/ /LO/ /LO/ A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a Firstline Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mrcc) (KEYNOTE-426) A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem A RANDOMIZED, MULTICENTER, DOUBLE- BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB- PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY. A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated with Talazoparib A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus (Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivolumab clinical Trial Evaluation 649) A Phase 1/1b Multicenter, Open-Label, Dose- Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI3726 in Subjects with Metastatic Castration Resistant Prostate Cancer (mcrpc) who have Received Prior Treatment with Abiraterone or Enzalutamide Yes 22/09/ /09/ /10/ /12/ /01/ /02/ /03/2017 Y Y Y Yes 06/06/ /09/ /03/ /10/ /04/ /04/ /04/2017 Yes 18/04/ /04/ /11/ /11/ /12/ /01/ /03/2017 Y Y Yes 26/01/ /09/ /01/ /12/ /01/ /01/ /01/2017 Yes 05/09/ /10/ /11/ /12/ /02/ /02/ /03/2017 Y Y Yes 10/10/ /07/ /07/ /04/ /07/ /08/ /08/2017 Y Yes 10/05/ /08/ /03/ /03/ /04/ /04/ /04/ /LO/ /SC/ /LO/ /EE/ The Use of 3D Surface Imaging to Simulate Outcomes after Breast Conserving Therapy Phase Ib, open-label, multi-center study to characterise the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589) A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2- negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease Yes 11/05/ /02/ /03/ /02/ /03/ /03/ /05/2017 Yes 03/04/ /11/ /03/ /01/ /03/ /03/ /03/2017 Yes 05/09/ /11/ /07/ /02/ /07/ /08/ /08/2017 Yes 07/04/ /09/ /02/ /01/ /03/ /03/ /04/ /NE/ /LO/ /LO/ An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION- RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN A phase III randomized, double-blind study comparing the combination of PDR001, dabrafenib and trametinib to the combination of dabrafenib and trametinib as first line therapy in patients with unresectable or metastatic BRAF V600 mutant melanoma with elevated LDH No 27/09/ /02/ /12/2016 Y sponsor declined site confirmation No 05/01/ /02/ /04/ /08/ /09/ /09/2017 Y Yes 02/02/ /02/ /02/ /03/ /03/ /03/ /04/ /EE/ A Multi-Center, Open-Label Trial Investigating the Efficacy and Safety of Continued Treatment with Tisotumab Vedotin in Patients with Solid Known to Express Tissue Factor Yes 29/08/ /02/ /06/ /05/ /07/ /08/ /08/2017 Y

3 17/LO/ /LO/ A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK in combination with androgen deprivation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC) A phase II study of the anti-pdl1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma No 23/11/ /09/ /08/ /09/ /09/2017 No 06/02/ /08/ /09/ /09/ /09/ /LO/ An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and/or recommended Phase II dose of the ATR inhibitor BAY in patients with advanced solid tumors and lymphomas Yes 15/08/ /06/ /06/ /07/ /07/ /07/ /07/ /LO/ /NE/ /EE/ /LO/ An Open-Label Multicenter Phase 1 Study of E7386 in Subjects with Selected Advanced Neoplasms A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-pd-1 Monoclonal Antibody, in Patients with Advanced Solid A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER Yes 26/07/ /05/ /05/ /06/ /07/ /07/ /07/2017 No 18/11/ /05/ /04/ /06/ /07/ /07/2017 Y Y No 28/02/ /03/ /06/ /05/ /06/ /08/2017 Y No 03/03/ /09/ /07/ /09/ /10/ /10/ /NW/ /YH/ Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or with Lenalidomide plus R-CHOP (R2 CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma Yes 16/08/ /11/ /04/ /05/ /06/ /06/ /06/2017 Y Y No 04/01/ /08/ /07/ /09/ /09/ /09/ /SC/ A PHASE 1B/2 OPEN-LABEL, RANDOMIZED STUDY OF 2 COMBINATIONS OF ISOCITRATE DEHYDROGENASE (IDH) MUTANT TARGETED THERAPIES PLUS AZACITIDINE: ORAL AG-120 PLUS SUBCUTANEOUS AZACITIDINE AND ORAL AG- 221 PLUS SC AZACITIDINE IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA HARBORING AN IDH1 OR AN IDH2 MUTATION, RESPECTIVELY, WHO ARE NOT CANDIDATES TO RECEIVE INTENSIVE INDUCTION CHEMOTHERAPY No 22/03/ /04/ /09/ /06/ /07/ /07/2017 Y Y 17/SW/ A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915: CHECKpoint pathway and nivolumab clinical Trial Evaluation 915) Yes 04/08/ /03/ /06/ /06/ /06/ /06/ /08/ /LO/ A Phase 2, Multicenter, International, Open- Label, Safety and Efficacy Study of INCB in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) No 15/03/ /09/ /07/ /09/ /09/ /10/ /NE/ A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-hodgkin s lymphoma (inhl) - CHRONOS-4 No 16/01/ /08/ /01/ /09/ /09/ /LO/ MUK nine b: OPTIMUM. A phase II study evaluating optimised combination of biological therapy in newly No 21/09/ /05/ /03/ /07/ /09/ /10/2017 Y Y diagnosed high risk multiple myeloma and plasma cell leukaemia. 17/SC/ MonarchE: Protocol I3Y-MC-JPCF A Randomized, No 13/03/ /07/ /07/ /08/ /08/ /09/2017 Y Y

4 14/LO/ A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic previously Untreated Esophageal Squamous Cell Carcinoma (CheckMate 648: CHECKpoint pathway and nivolumab clinical Trial Evaluation 648) No 07/03/ /09/ /08/ /09/ /10/ /10/ /SW/ /NW/ /YH/ A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib. A Phase 1/2, open-label, multicentre, dose escalation and dose expansion study of NKTR- 214 and Nivolumab in patients with select locally advanced or metastatic solid tumor malignancies No 15/02/ /07/ /05/ /07/ /07/2017 Y Yes 05/10/ /05/ /05/ /07/ /08/ /08/ /09/2017 Y Y No 05/09/ /08/ /07/ /09/ /09/ /10/ /LO/ /EM/ A Phase 1/1b Study of Paclitaxel in Combination with BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients with Advanced Nonhaematologic Malignancies ElevatION:CRC-101: A Phase Ib study of PDR001 in combination with bevacizumab and mfolfox6 as first line therapy in patients with metastatic MSS colorectal cancer No 14/06/ /09/ /10/ /10/ /10/2017 No 15/05/ /09/ /09/ /09/ /09/ /09/ /EM/ /EE/ /NI/ /LO/ A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML A Phase 1, Open-Label, Multicentre, Non- Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects with Relapsed or Refractory Haematological Malignancies Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis BARCODE 2 - Targeting cancer care with the use of genetic profiling No 09/12/ /07/ /07/2017 No 27/09/ /09/2017 No 04/01/ /05/ /08/ /06/ /06/ /07/2017 Y Y Yes 25/10/ /03/ /04/ /05/ /05/ /05/ /05/ /EM/ /LO/ A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B- cell non-hodgkin Lymphoma A randomised phase I/II study of Intensity Modulated Arc Therapy techniques in abdominal neuroblastoma No 08/03/ /10/ /10/ /02/ /05/ /07/2017 Y Yes 24/01/ /01/ /01/ /02/ /02/ /02/ /02/ /EM/ /SC/ LCH- IV International Collaborative Treatment Proto col for Children and Adolescents with Langerhans Cell Histiocytosis COMET Concordance in MRI and Pathology Diagnosis of Extranodal Tumour Deposits No 08/02/ /04/ /07/ /03/ /06/ /07/2017 Y Y Yes 21/07/ /09/ /10/ /09/ /10/ /10/ /10/ /LO/ Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (Biomede) No 23/02/ /04/ /04/ /07/ /07/ /10/2017 Y 17/WM/ /LO/ /LO/ Paediatric Hepatic International Tumour Trial An international prospective study on clinically standard risk medulloblastoma in children older than 3 years with lowrisk biological profile (PNET 5 MB LR) or average risk biological profile (PNET 5 MB SR) SIOP PNET 5 Medulloblastoma DARS: a phase III randomised multicentre study of dysphagia optimized intensity modulated radiotherapy (Do-IMRT) versus standard intensity modulated radiotherapy (s-imrt) in head and neck cancer Yes 20/10/ /06/ /07/ /04/ /07/ /09/ /09/2017 Y Y No 20/07/ /07/ /10/ /08/ /09/2017 Yes 24/05/ /09/ /11/ /06/ /12/ /01/ /03/2017 Y 07/Q0703/ Improving Outcomes in Robotic and Endoscopic Surgery using Augmented Reality Guidance Yes 20/01/ /03/ /12/ /12/ /03/ /01/ /01/ /LO/ Assessing the accuracy of lung radiotherapy using fiducial markers for verification during fractionated external beam radiotherapy. No 14/07/ /12/ /04/ /04/ /04/2017 Y 16/NE/ /WM/ A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after chemo-radiotherapy A phase II trial of pembrolizumab in patients with non-small cell lung cancer and a performance status of 2 No 14/10/ /04/ /04/ /04/ /05/ /05/2017 Y Y Yes 10/06/ /10/ /06/ /10/ /11/ /11/ /11/ /SC/ An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + Cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Yes 03/04/ /09/ /12/ /02/ /02/ /02/ /02/2017 Y Y 16/LO/ AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT Yes 12/05/ /10/ /11/ /01/ /03/ /04/ /04/2017 Y Y

5 16/LO/ /EM/ /WM/ A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum- Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma A Phase 3 Multicenter Open-label Study of Brigatinib versus Crizotinib Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. A randomised phase III trial. No 07/11/ /11/ /11/ /08/ /09/2017 Y Yes 05/04/ /03/ /07/ /05/ /05/ /06/ /05/2017 Y Y No 06/10/ /11/ /05/2016 Y 16/EE/ A Phase 2 Efficacy and Safety Study of Niraparib in men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies Yes 30/03/ /10/ /11/ /01/ /03/ /03/ /03/2017 Y 16/LO/ An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Yes 29/03/ /10/ /03/ /12/ /03/ /03/ /03/ /SC/ /EE/ A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (CheckMate 714) Phase I Open Label, Multicenter Study of MK Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patinets with Advanced/Metastatic Solid or Lymphomas Yes 13/04/ /11/ /03/ /02/ /03/ /04/ /04/2017 Yes 13/07/ /02/ /04/ /03/ /05/ /05/ /07/2017 Y 17/LO/ A randomized phase III study of pembrolizumab given concomitantly to chemoradiation and as maintenance therapy versus chemoradiation alone in patients with locally advanced squamous cell carcinoma of the head and neck No 20/03/ /08/ /04/ /09/ /10/ /10/ /LO/ /SC/ /LO/ AN EXPLORATORY TUMOR BIOPSY-DRIVEN STUDY TO UNDERSTAND THE RELATIONSHIP BETWEEN BIOMARKERS AND CLINICAL RESPONSE IN IMMUNOMODULATORY TREATMENT-NAIVE PATIENTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK RECEIVING REGN2810 (ANTI-PD-1) A multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency Yes 31/08/ /01/ /05/ /04/ /07/ /07/ /08/2017 Y Y Yes 05/09/ /03/ /05/ /06/ /06/ /07/ /09/2017 Y Y No 11/05/ /08/ /03/ /08/ /08/ /08/ /NE/ A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer No 16/05/ /06/ /12/ /09/ /09/ /09/2017 Y 16/SC/ Testing Radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility trial No 07/08/ /08/ /10/ /SS/ A randomised phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma Yes 04/09/ /11/ /02/ /10/ /04/ /04/ /04/2017 Y Y